Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use ACE-031. Talk to a licensed clinician before making health decisions.

What it is

ACE-031 is a recombinant fusion protein containing the extracellular domain of the activin receptor type IIB linked to an immunoglobulin Fc domain. By binding myostatin, activin A, and related transforming growth factor-beta ligands, it removes a brake on muscle growth. It was developed for Duchenne muscular dystrophy.

What the evidence shows

Phase 1 and 2 trials in Duchenne muscular dystrophy showed dose-dependent increases in lean mass and improvements in some muscle-function endpoints. However, development was paused due to safety signals, including nosebleeds, gum bleeding, and telangiectasias (small blood-vessel lesions). It remains investigational.

Risks & unknowns

Phase trials revealed bleeding events, skin vascular lesions (telangiectasias), and potential effects on the reproductive system due to broad ligand inhibition. Long-term safety, including effects on the heart, vessels, and cancer risk, is unknown.

Legal / regulatory status

ACE-031 is not FDA-approved. It is prohibited by WADA under S2. It is not legal to market for human use.